Difference between revisions of "The Compendium of Cancer Genome Aberrations"
[unchecked revision] | [unchecked revision] |
Line 8: | Line 8: | ||
*For contributors, we've created a '''<u>[[Video_Tutorial|Video Tutorial]]</u>''' demonstrating how to add content to the CCGA. Please also refer to helpful '''<u>[[Author Instructions|Author Instructions]]</u>''' | *For contributors, we've created a '''<u>[[Video_Tutorial|Video Tutorial]]</u>''' demonstrating how to add content to the CCGA. Please also refer to helpful '''<u>[[Author Instructions|Author Instructions]]</u>''' | ||
+ | |||
{{Box-round|title=Newest Items|titlebackground=#06B5AD|Explore the great content available in '''<u>[[Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms|Acute Myeloid Leukemia (AML)]]</u>''', '''<u>[[Myelodysplastic Syndromes (MDS)|Myelodysplastic Syndrome (MDS)]]</u>''', '''<u>[[Myeloproliferative Neoplasms (MPN)|Myeloproliferative Neoplasms (MPN)]]</u>''', and '''<u>[[Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)]]</u>'''. | {{Box-round|title=Newest Items|titlebackground=#06B5AD|Explore the great content available in '''<u>[[Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms|Acute Myeloid Leukemia (AML)]]</u>''', '''<u>[[Myelodysplastic Syndromes (MDS)|Myelodysplastic Syndrome (MDS)]]</u>''', '''<u>[[Myeloproliferative Neoplasms (MPN)|Myeloproliferative Neoplasms (MPN)]]</u>''', and '''<u>[[Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)]]</u>'''. |
Revision as of 14:49, 7 February 2021
Welcome to the Compendium of Cancer Genome Aberrations (CCGA)! The CCGA is a collaborative effort to document and describe chromosome and other genomic abnormalities in cancer. The Wiki style interface allows for real-time editing and content sharing within our genetics community. This resource is supported by the Cancer Genomics Consortium (CGC) and others with an interest in clinical cytogenetics, molecular genetics and genomics in cancer.
- Join the CCGA community! If you would like to contribute as an author, please complete a few brief questions on our Volunteer Form.
- Contact us for more information or suggestions for updates.
- Meet our editorial Leadership.
- For contributors, we've created a Video Tutorial demonstrating how to add content to the CCGA. Please also refer to helpful Author Instructions
Diseases A
| B | C | D | E | F
| G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U
| V | W | X | Y | Z
Structural Abnormalities 1
| 2 | 3 | 4
| 5 | 6
| 7 | 8 | 9
| 10 | 11 | 12
| 13 | 14 | 15
| 16 | 17 | 18
| 19 | 20 | 21
| 22 | X | Y
Cancer Genes A
| B | C | D | E | F
| G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U
| V | W | X | Y | Z
Cancer Genomes Hematologic and Lymphoid | Solid Tumors | CNS | Pediatric
Notice and Disclaimer/Limitation of Liability of Resource Use
Data and information obtained from the Cancer Genomics Consortium (CGC) and the Compendium of Cancer Genome Aberrations (CCGA) is provided as an educational resource only. These data are provided on an "AS IS" basis, without representation or warranty of any kind, including without limitation the warranties of merchantability, fitness for a particular purpose and non-infringement. Availability of this data and information does not constitute scientific publication. Data and/or information may contain errors or be incomplete.
The CGC, CCGA and all participating entities make no representation or warranty, express or implied, including without limitation any warranties of merchantability or fitness for a particular purpose or warranties as to the identity or ownership of data or information, the quality, accuracy or completeness of data or information, or that the use of such data or information will not infringe any patent, intellectual property or proprietary rights of any party.
The CGC and CCGA shall not be liable for any claim for any and all loss, harm, illness or other damage or injury arising from access to or use of data or information howsoever caused, including without limitation, any direct, indirect, incidental, exemplary, special or consequential damages, even if advised of the possibility of such damages. The data and information obtained from the Cytogenomics Array Group database shall not be used as a substitute for the user's skills, expertise and experience.